MS Society disappointed over Elan drug deaths

The head of the Multiple Sclerosis Society of Ireland has described news that a second patient being treated with the new MS drug, Tysabri, has developed a rare neurological virus as "very disappointing".

Shares in Elan, the pharmaceutical company which produces the drug and has bases in Ireland, plunged again following the confirmation.